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OBJECTIVES: To estimate outcomes according to
attained blood pressure (BP) in the oldest adults treated
for hypertension in routine family practice.
DESIGN: Cohort analysis of primary care inpatient and
death certificate data for individuals with hypertension.
SETTING: Primary care practices in England (Clinical
Practice Research Datalink).
PARTICIPANTS: Individuals aged 80 and older taking
antihypertensive medication and free of dementia, cancer,
coronary heart disease, stroke, heart failure, and end-stage
renal failure at baseline.
MEASUREMENTS: Outcomes were mortality, cardiovas-
cular events, and fragility fractures. Systolic BP (SBP) was
grouped in 10-mmHg increments from less than 125 to
185 mmHg or more (reference 145–154 mmHg).
RESULTS: Myocardial infarction hazards increased lin-
early with increasing SBP, and stroke hazards increased for
SBP of 145 mmHg or greater, although lowest mortality
was in individuals with SBP of 135 to 154 mmHg. Mortal-
ity of the 13.1% of patients with SBP less than 135 mmHg
was higher than that of the reference group (Cox hazard
ratio=1.25, 95% confidence interval=1.19–1.31; equating
to one extra death per 12.6 participants). This difference
in mortality was consistent over short- and long-term fol-
low-up; adjusting for diastolic BP did not change the risk.
Incident heart failure rates were higher in those with SBP
less than 125 mmHg than in the reference group.
CONCLUSION: In routine primary care, SBP less than
135 mmHg was associated with greater mortality in the
oldest adults with hypertension and free of selected poten-
tially confounding comorbidities. Although important con-
founders were accounted for, observational studies cannot
exclude residual confounding. More work is needed to
establish whether unplanned SBPs less than 135 mmHg in
older adults with hypertension may be a useful clinical
sign of poor prognosis, perhaps requiring clinical review of
overall care. J Am Geriatr Soc 65:995–1003, 2017.
Key words: hypertension; outcomes; mortality; oldest
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Hypertension is the most common chronic condition inolder people,1 yet there is debate about treatment
targets and longer-term adverse event rates, especially in
the oldest adults. Current guidelines for adults aged 80
and older recommend upper systolic blood pressure
(SBP) treatment targets varying from 150 mmHg2–5 to
140 mmHg.6 Although there is accumulating evidence on
the efficacy of antihypertensive treatment in older adults
from randomized trials, less information is available on
the overall prognosis for the oldest adults with hyperten-
sion treated under current guidelines, especially over the
long term.7
The current study used electronic medical record data
from a large, nationally representative population regis-
tered with primary care practices in England in the Clini-
cal Practice Research Datalink (CPRD) database8 to
estimate overall prognosis according to attained SBP in the
oldest adults in routine family practice, working under
national guidance to achieve a SBP less than 150 mmHg.
Associations between attained SBP and all-cause mortality,
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cardiovascular events, and fragility fractures were esti-
mated in older adults undergoing treatment for hyperten-
sion. The goal was to estimate prognosis in individuals
without comorbidities who might require specialized treat-
ment or bias results (aiming to minimize confounding);
thus, participants were free of dementia, recent cancer,
stroke, heart failure, coronary heart disease, or end-stage
renal failure at baseline. An extensive set of sensitivity
analyses was also performed to examine the effects of sug-
gested additional confounders.
METHODS
Data Source
The CPRD is the English National Health Service (NHS)
observational data service, with more than 11.3 million
patients from 674 U.K. primary care practices.8 CPRD
data from primary care linked to Hospital Episode Statis-
tics (HES) data for hospital admissions and diagnosis and
Office for National Statistics (ONS) death certificate data
were used. The data include information on individuals
living in institutionalized care settings, as well as commu-
nity-dwelling older people, and registration with primary
care is very near complete for the older population in Eng-
land.8 The data have been shown to be representative of
the U.K. population in terms of age and sex.8
Study Population
All adults in CPRD aged 80 and older with diagnosed
hypertension who had at least three blood pressure (BP)
measurements during a 3-year lead-in period and were pre-
scribed at least one class of antihypertensive medication
(alpha-blockers, angiotensin-converting enzyme inhibitors,
angiotensin receptor antagonists, beta-blockers, calcium
channel blockers, centrally active antihypertensives, diuret-
ics, renin inhibitors) before the lead-in period and during
the follow-up period were included. The distribution of
the classes of antihypertensive medication prescribed
according to attained blood SBP is shown in Table S1. The
earliest start date for the lead-in period was January 1,
2000. Primary care Read (diagnostic) codes as defined by
NHS Quality of Outcomes Framework rules9 and Interna-
tional Classification of Diseases, Tenth Revision (ICD-10)
codes in HES10 were used to identify individuals with
hypertension.
Individuals with comorbidities that require specialized
treatment or might introduce confounding (reverse causa-
tion with the comorbidity reducing BP) were excluded.
Diagnoses excluded at baseline were dementia, cancer,
stroke, heart failure, coronary heart disease, and end-stage
renal failure (diagnosis of chronic kidney disease Stage 5
from CPRD or HES or dialysis code in CPRD, HES, or
Office of Population Censuses and Surveys Classification of
Interventions and Procedures version 4) (Figure S1)(10, 11).
Sensitivity analyses on the effect of excluding individuals
with diabetes mellitus or chronic obstructive pulmonary
disease (conditions that might particularly affect manage-
ment of hypertension in their late stages) on all-cause mor-
tality did not significantly alter results, so such individuals
were not excluded (Table S2).
BP Data
BP was measured during routine general practitioner (GP)
visits and recorded by the GP, nurse, or other practice staff,8
normally in a sitting position at rest.4 Measurements were
excluded if they did not record SBP and diastolic BP (DBP).
Individual measurements with extreme values (<0.15 and
>99.85 centile) (SBP: <85 mmHg and > 224 mmHg; DBP:
<46 mmHg and >120 mmHg) were excluded. The median
of BP measurements recorded during the lead-in period were
used to estimate stable treated baseline SBP and DBP; the
median was used to avoid biases from extreme measures
during acute clinical events. The average number of BP mea-
surements according to SBP category varied from 7.2 for less
than 125 mmHg to 13.4 for 165 to 174 mmHg (Table S3);
15,265 individuals diagnosed with and treated for hyperten-
sion had fewer than three BP measurements (Figure S1).
This excluded group had a higher prevalence of dementia
and heart failure at baseline, which would have triggered
exclusion anyway. (This group may have fewer BPs
recorded in primary care because of greater specialist input
in secondary care.) Median SBP was categorized as less than
125 mmHg, 125 to 134 mmHg, 135 to 144 mmHg, 145
to 154 mmHg, 155 to 164 mmHg, 165 to 174 mmHg, 175
to 184 mmHg, and 185 mmHg and greater.
Covariates
Sex, age at beginning of follow-up, quintile of 2010 English
Index of Multiple Deprivation for England (based on GP’s
postcode, as a proxy for socioeconomic status), and smok-
ing status (from recorded GP Read terms, classified as cur-
rent or recent smoker, exsmoker, and never smoker over
the 10 years before study entry) were adjusted for in the
statistical modelling. Adjusting for year of beginning of fol-
low-up did not significantly affect estimates, so it was not
included in the final models. Sensitivity analyses of the
effect of comorbidity (Charlson Comorbidity Index12),
major weight loss (a history of weight loss of ≥10% in the
5 years before baseline), body mass index (BMI), and exclu-
sion of individuals in institutional settings on the associa-
tion between SBP and all-cause mortality did not
significantly alter the results. Individuals in institutional set-
tings during the 3-year lead-in period of analysis were iden-
tified through recorded contacts in residential or nursing
homes with doctors or other practice staff. When testing for
confounding, stratified survival analyses were selected when
adjustment for the tested covariate violated hazard propor-
tionality.13 Therefore, because this analysis aimed to esti-
mate overall prognosis for the defined complete group of
typical patients, individuals were not excluded based on
these factors. Neither were these factors further adjusted
for in the main analyses, because that might have adjusted
away intermediate pathology on the causal pathway to out-
comes, potentially introducing bias, and would have made
estimates difficult to interpret for routine clinical practice.14
Outcomes
The outcomes of interest for this analysis were all-cause
mortality, cardiovascular events (ischemic stroke, myocar-
dial infarction (MI), heart failure), and fragility fractures.
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Outcomes were considered if the event occurred while the
participant was registered with a practice and the practice
data quality was classified as up-to standard according to
CPRD. Fragility fractures are pathological fractures that
occur as part of normal activities such as falling from a
standing height and are often associated with osteoporo-
sis.15 Only the commonest fragility fractures were
included, to increase specificity: hip, vertebrae, humerus,
distal radius, pelvis or pubic ramus, and ankle. Data for
outcomes were obtained from participant HES data. For
MI and fragility factors, ICD-10 codes were supplemented
with procedural coding from Office of Population Cen-
suses and Surveys Classification of Interventions and Pro-
cedures version 4 (10, 11).
Statistical Analysis
Cox proportional hazards models were used to estimate
associations between BP and mortality outcomes. Compet-
ing-risk survival models were used for incident stroke, MI,
heart failure, and fragility fractures, with all-cause mortal-
ity as a competing risk.16 For all survival analyses, the
attained SBP of 145 to 154 mmHg (with midpoint
150 mmHg) was used as the reference category, because it
lies within most international BP targets for older peo-
ple.17 For all outcomes, the numbers needed to treat or
harm were calculated using the Altman and Anderson
method.18 All statistical analyses were conducted using
Stata version 13 (Stata Corp., College Station, TX). In the
main analyses, 12,854 individuals were excluded because
of missing information on smoking habits, and an addi-
tional 32 were excluded for missing information on Index
of Multiple Deprivation (Figure S1).
Ethical and Scientific Approval
The CPRD has been granted multiple research ethics com-
mittee approval (05/MRE04/87) to undertake purely
observational studies, with external data linkages including
HES and ONS mortality data. The work of CPRD is also
covered by National Information Governance Board for
Health and Social Care Ethics and Confidentiality Com-
mittee approval ECC 5–05 (a) 2012.
RESULTS
Data were from 79,376 individuals aged 80 and older who
met inclusion criteria for the analysis. Mean age was
82.1  3.3, and 30.5% were men (Table 1). The average
number of BP measurements according to SBP category
varied from 7.2 for SBP less than 125 mmHg to 13.4 for
SBP of 165 to 174 mmHg (Table S3). There were trends
in covariates across SBP (e.g., current or recent smoking
24% at SBP <125 mmHg and 18% at SBP >185 mmHg)
(Table 1). Maximum follow-up was 11.9 years (overall
mean 4.4  2.9 years), with mean follow-up times some-
what shorter in the low SBP groups.
All-cause Mortality According to Attained SBP
During follow-up, 25,543 patients died (Table 1). Mortal-
ity hazards showed a U-shaped pattern (Figure 1, Table 2),
with lowest mortality in individuals with SBP of 135 to
154 mmHg (hazard ratio (HR) = 1.03, confidence interval
(CI) = 0.99–1.06, risk is essentially the same as that of the
comparison group of SBP 145–154 mmHg) and greater
mortality for higher levels of SBP. The risk of mortality
was greater for SBP less than 135 mmHg (combining the
two lowest SBP categories, 13.1% of participants)
(HR=1.25, 95% CI=1.19–1.31). This excess risk is equiva-
lent to one extra death for every 13 individuals aged 80
and older with SBP less than 135 than for the comparison
group based on number needed to harm estimation. Mor-
tality hazard was estimated separately in 2-year follow-up
segments to check for stability between short- and longer-
term outcomes (Table S4). Lower attained SBP
(<135 mmHg) was associated with greater mortality in all
follow-up periods, although estimates for the first 2 years
were higher (HR = 1.38, 95% CI = 1.26–1.51) than, for
example, at 6 to 8 years follow-up (HR = 1.19, 95%
CI = 1.07–1.32), albeit with overlapping confidence inter-
vals. Central estimates of mortality hazard were higher
again from 8 years to end of follow-up (HR = 1.29, 95%
CI = 1.09–1.53), although in small numbers of partici-
pants.
To test for modifying effects of DBP, DBP was
grouped into 85 mmHg and higher, 70 to 84 mmHg, and
less than 70 mmHg (estimates with more-extreme groups
were underpowered). The U-shaped pattern of systolic
mortality hazard was similar for all three DBP groups
(Table 3, Figure S2). The modifying effect of pulse pres-
sure on all-cause mortality was also tested by adjusting the
model for five levels of pulse pressure (<50 mmHg, 50–
59 mmHg (reference), 60–69 mmHg, 70–79 mmHg,
≥80 mmHg). A significantly greater risk of all-cause mor-
tality remained in those with low BP even when adjusted
for pulse pressure (<125 mmHg: HR = 1.33, 95%
CI = 1.2–1.48, P < .001; 125–134 mmHg: HR = 1.15,
95% CI = 1.08–1.22, P < .001).
An interaction term and analysis stratified according
to sex (Table S5) demonstrated that differences according
to sex were not significant. An analysis of similarly
selected individuals with one or two recorded blood pres-
sure measures (n = 5,012) in the 3 years before baseline
resulted in a similar risk curve to that of individuals with
3 or more measurements (Table S6). Sensitivity analyses
adjusted for and stratified according to level of comorbid-
ity (Charlson Comorbidity Index12), major weight loss
(≥10% in 5 years before baseline), or BMI or excluding
individuals with consultations in institutional settings dur-
ing the baseline period; in all cases, mortality at low SBP
(<135 mmHg) remained significantly greater. Analyses
adjusting for and excluding individuals with diabetes melli-
tus and with chronic obstructive pulmonary disease had
similar results (Table S2).
Incident Disease
There was an approximately linear increase in risk of inci-
dent MI across the SBP range (Figure 2), with lower SBP
associated with lower risk (<125 mmHg: HR = 0.6, 95%
CI = 0.43–0.84, number needed to treat 9.8; 125–
134 mmHg: HR = 0.78, 95% CI = 0.67 to 0.92, number
needed to treat 25.8) than the SBP 145 to 154 mmHg
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(Table 2, Table S7). Risk of incident stroke was greater at
SBP above 145 to 154 mmHg (Figure 2).
During follow-up, 7,882 individuals developed heart
failure (Table 1). Competing subhazards for incident heart
failure rose progressively at SBP above 145 to 154 mmHg,
but there was also greater risk for lower SBP (e.g., SBP
<125 mmHg: HR = 1.2, 95% CI = 1.02–1.4, number
needed to harm 28.6) (Figure 2, Table 2).
During follow-up, 7,360 individuals were admitted to
hospital with a fragility fracture or had surgical interven-
tion for a hip fracture (follow-up mean 4.4  2.9 years).
Risk of fracture was not different for different SBP, with
no indication of greater risk with low SBP.
Confounding of the association between SBP less than
135 mmHg and greater mortality might theoretically have
been due to undiagnosed cancer present at baseline, but
cancer incidence during the 11.9 years of follow-up was
not significantly different (and tended to be lower) in those
with (e.g., HR = 0.93, 95% CI = 0.81–1.06) SBP less than
125 mmHg. The highest cancer incidence was in the refer-
ence group of SBP 145 to 154 mmHg, and cancer inci-
dence was significantly lower at SBP greater than
175 mmHg (e.g., HR = 0.85, 95% CI = 0.75–0.95) for
SBP of 175 to 184 mmHg. Although there were no data
on why cancer incidence was lower in the low and high
SBP categories, an analysis for all-cause mortality adjusted
for incident cancer, and separate analyses for individuals
with and without incident cancer, did not significantly
alter results (Table S8).
DISCUSSION
A large cohort of the oldest adults in primary care taking
antihypertensive medication over the long term was stud-
ied to estimate prognosis according to attained BP level in
routine primary care practice working under national guid-
ance to achieve a SBP less than 150 mmHg in older adults
with hypertension. Individuals with major comorbidities at
baseline that might have posed specialist treatment chal-
lenges or confounded estimates were excluded. The analy-
sis included 49.7% of individuals aged 80 and older in the
complete population-based analysis. It was found, as
expected, that all-cause mortality and risk of cardiovascu-
lar disease rose with increasing SBP above 145 to
154 mmHg. Linearly increasing risk of myocardial
Figure 1. Risk of all-cause mortality according to systolic
blood pressure.
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infarction was found with increasing SBP, although greater
mortality was also found in those with SBP of less than
135 mmHg. Confounding is typically evident in the first
few years of follow-up, but the excess mortality at SBP less
than 135 mmHg was consistent, even over the longest fol-
low-up period (8–11.9 years) Table S4. The sensitivity
analyses on comorbidity, BMI, major weight loss, incident
cancer, and exclusion of those seen by practice staff in res-
idential or nursing homes also had little effect on esti-
mates. Results were also similar in individuals with
diabetes mellitus (Table S2).
These results reflect outcomes of individuals aged 80
and older receiving ongoing treatment for hypertension
under currently recommended targets; at the time the data
were recorded in electronic clinical records, intensive
treatment to reduce SBP below 140 mmHg in individuals
aged 80 and older was not indicated. Observational stud-
ies of prognosis in the above context are not comparable
with studies that randomize participants to intensive treat-
ment to achieve lower target BP. If intensive treatment
were instituted to achieve SBP substantially lower than
150 mmHg, those with low SBP might be expected to be
taking more antihypertensive medications than those with
higher attained BP, but the group with lower attained
SBP (<125 mmHg) had slightly fewer prescribed medica-
tions (mean 1.84) than the reference group (mean 1.99
for SBP 145–154 mmHg). Also, the participants being in
routine care, the medications prescribed may have differed
from those used in recent trials aiming to achieve lower
SBP. This analysis has other limitations, including inaccu-
racies in routine data recording. Although routine practice
is to measure BP more than once for each clinical review,
the available data contain only one recorded BP at each
consultation, although it seems likely that the BPs
recorded in clinical records are those used as a basis for
management. Inaccuracies in estimated BPs were mini-
mized by using median of recorded BPs across consulta-
tions during a 3-year lead-in period, avoiding “outliers”
(perhaps recorded during acute events) that might distort
mean values, and the mean number of measurements
studied varied from 7.2 for the group with SBP less than
125 mmHg to 13.4 for those with SBP of 165 to
174 mmHg (Table S3). The studied BPs were used in
monitoring antihypertensive treatment and thus have
Table 3. Risk of All-Cause Mortality According to Systolic Blood Pressure (SBP) (Reference 145–154 mmHg) and
Diastolic Blood Pressure (DBP)
DBP,
mmHg
SBP, mmHg
<125 125–134 135–144 155–164 165–174 175–184 >185
<70 1.40 (1.16–1.70)a 1.25 (1.07–1.46)a 1.06 (0.93–1.21) 1.12 (0.95–1.32) 1.20 (0.94–1.54) 1.49 (1.05–2.10)a 1.58 (0.82–3.07)
70–84 1.50 (1.35–1.66)a 1.20 (1.13–1.27)a 1.04 (1.00–1.08) 1.05 (1.00–1.09)a 1.13 (1.07–1.20)a 1.24 (1.14–1.35)a 1.38 (1.21–1.58)a
≥85 1.05 (0.47–2.34) 1.36 (1.11–1.66)a 1.00 (0.91–1.09) 1.05 (0.99–1.12) 1.15 (1.07–1.24)a 1.13 (1.03–1.23)a 1.27 (1.13–1.42)a
Survival analysis of all-cause mortality according to SBP level stratified according to DBP.
aP<.05.
Figure 2. Risk of all-cause mortality and systolic blood pressure according to diastolic blood pressure.
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validity for the purpose of estimating prognosis in routine
practice. Other aspects of BP, including orthostatic
hypotension, have been associated with adverse events
and may have contributed to the results observed,19 algh-
outh no data are available on orthostatic hypotension in
the dataset. Although assessment of orthostatic hypoten-
sion is thought to be common, the lack of specific data
on these measures limits this analysis. Given the “typical
care” rather than etiological context, BP measured during
follow-up (e.g., accounting for regression dilution)20 was
not accounted for because subsequent BP measurement
were not available at treatment review in practice. Anti-
hypertensive medication data are from real-time prescrib-
ing records; no measure of adherence was available,8
although nonadherence should be associated with higher
BP and was unlikely to bias estimates of greater mortality
at low SBP. Cause-specific mortality was not studied,
because death certification is thought to lack precision in
the oldest adults, especially for cardiac outcomes. Records
of lower SBP were more common in the later part of the
period (2000–2014), with shorter mean follow-up times
for individuals with low SBP (Table 1). This may have
been the result of incentive payments to improve hyper-
tension management introduced from 2004, but adjusting
for year of baseline BP measurement did not significantly
alter results.21 Elaborate adjustment of models was also
avoided, with potentially confounding conditions excluded
instead and easily interpretable estimates of prognosis in
routine primary care provided. It is also possible that
there was some undiagnosed disease at baseline that
reduced BP and increased mortality, but low SBP was
associated with excess mortality even in the 8 years to
the end of follow-up (ignoring the first 8 years of follow-
up), making this explanation less likely. The Charlson
Comorbidity Index was used to account for comorbidities,
but this does not fully capture functional status or frailty
in this population; better measurement of functional sta-
tus or frailty (e.g., gait speed) might correlate with the
poor outcomes in the lower SBP group, although the
study subjects were selected to be free of dementia, can-
cer, stroke, heart failure, coronary heart disease, and end-
stage renal disease, and adjustment for Charlson comor-
bidities altered the results only slightly, as did any of the
other sensitivity analyses.
In the United Kingdom, 98% of the population are
registered with a GP, and the CPRD sample was found to
be broadly representative of English population based on
the 2011 Census, particularly in older age groups.8 Longer
follow-up was included than in existing studies in adults
aged 80 and older.22 Randomized trials provide the most
robust evidence of causation by tested treatments, observa-
tional population representative studies are also useful for
estimating overall clinical prognosis (combination of anti-
hypertensive effects and all other factors, measured and
unmeasured). Observational studies are useful for investi-
gating applicability to typical patient groups, longer fol-
low-up times, and adverse outcomes.23,24
Comparison with Previous Evidence
These results are restricted to the oldest adults undergoing
antihypertensive treatment and focus on clinical prognosis
in routine care. The finding of J-shaped associations for
some outcomes is broadly consistent with previous evidence
for individuals aged 80 and older in studies of individuals
with high cardiovascular risk.25–27 The Clinical research
using LInked Bespoke studies and Electronic health Records
(CALIBER) study also used CPRD GP medical records and
linked data to study cardiovascular outcomes in individuals
taking antihypertensive medications. In their subgroup aged
80 to 95 taking antihypertensive medications (with no
exclusions for non-CVD comorbidities, Table S15), increas-
ing SBP was similarly associated with a linear increase in
incident myocardial infarction, plus a J-shaped association
for heart failure and a flat association with ischemic stroke
for SBP less than 159 mmHg.23 CALIBER did not study
all-cause mortality or fragility fracture outcomes. CALIBER
reported “unheralded” CHD mortality based on death cer-
tification in people without a history of cardiovascular dis-
ease and found markedly higher mortality at low SBP in
those aged 80 to 95 (SBP 100–115 mmHg: HR = 1.27,
95% CI = 1.09–1.48; SBP 140–159 mmHg: HR = 0.60,
95% CI = 0.43–0.84). The Prospective Studies Group
pooled volunteer cohorts from the 1960s to the 1980s and
found a linear association between BP (irrespective of treat-
ment) and vascular and overall mortality in adults aged 80
and older (published 2002), but it is uncertain how these
findings relate to older adults with treated hypertension in
the current treatment era.24
The observational data of outcomes in routine care
focus on a different concern and are not comparable with
data from randomized controlled trials, although the
HYpertension in the Very Elderly Trial—a randomized
controlled trial of hypertension management in adults aged
80 and older—showed lower all-cause mortality28 with a
target BP of 150/80 mmHg and an achieved mean sitting
BP of 145.0/76.6 mmHg in the active treatment group at
the start of the open-label extension. The Systolic Blood
Pressure Intervention Trial in Patients Age 75 and Older
(SPRINT 75+) aimed “To evaluate the effects of intensive
(<120 mmHg) compared with standard (<140 mmHg) SBP
targets in persons aged 75 years or older with hyperten-
sion but without diabetes”.29 SPRINT included 1,317
cases and 1,319 controls aged 75 and older (37.9%
female) free of diabetes mellitus, stroke, a recent cardio-
vascular event or heart failure, dementia, medical condi-
tions limiting life expectancy to less than 3 years
(including cancer), and factors that the clinic team judged
to be likely to limit adherence to therapy, or residence in a
nursing home. SPRINT 75+ concluded that “intensive
treatment resulted in significantly lower rates of fatal and
nonfatal major cardiovascular events” over a median fol-
low-up of 3.14 years. There were also nonsignificant
trends toward higher rates of some adverse events, except
for injurious fracture, which was nonsignificantly less com-
mon in the intensive treatment group (4.9% vs 5.5%).
More work is needed to include measures of ortho-
static hypotension and to identify the reasons for the
apparently poor prognosis of individuals with SBP less
than 135 mmHg in routine care. It may be that
unplanned low attained SBP may be a useful clinical sign
to trigger general clinical review of all comorbidities.
Better measurement of frailty and functioning may be
informative.
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CONCLUSIONS
In a complete population of individuals with hypertension
in primary care aged 80 and older treated under guidance
to achieve SBP less than 150 mmHg, greater mortality was
found over 11.9 years of follow-up in those with SBP of
less than 135 mmHg. More work is needed to establish
whether unplanned SBP of less than 135 mmHg in older
adults with hypertension may be a useful clinical sign of
poorer prognosis requiring overall clinical review of care.
ACKNOWLEDGMENTS
Financial Disclosure: This work was supported in part by
the National Institute for Health Research (NIHR) School
for Public Health Research Ageing Well programme.
School for Public Health Research is a partnership
between the universities of Sheffield, Bristol, and Cam-
bridge; University College of London; the London School
for Hygiene and Tropical Medicine; the University of Exe-
ter Medical School; the LiLaC collaboration between the
Universities of Liverpool and Lancaster and Fuse; and the
Centre for Translational Research in Public Health, a col-
laboration between Newcastle, Durham, Northumbria,
Sunderland and Teesside Universities.
Conflict of Interest: Drs. Delgado, Masoli, and Ble
have grant support from the NIHR for the submitted
work. Dr Strain reports personal fees from Pfizer, Boehrin-
ger Ingelheim, and MSD; grants and personal fees from
Novartis and Novo Nordisk outside the submitted work.
The other authors report no disclosures.
Author Contributions: Dr. Delgado and Professor Mel-
zer had full access to all the data in the study and take
responsibility for the integrity of the data and the accuracy
of the data analysis. Masoli, Delgado, Ble, and Melzer:
Study concept and design; All authors: Acquisition, analysis,
or interpretation of data; Masoli, Delgado, Ble and Melzer:
Drafting of the manuscript. All authors: Critical revision of
the manuscript for important intellectual content. Delgado,
Bowman, Masoli, Ble and Melzer: Statistical analysis.
Sponsor’s Role: The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
REFERENCES
1. Melzer D, Tavakoly B, Winder RE et al. Much more medicine for the oldest
old: Trends in UK electronic clinical records. Age Ageing 2015;44:46–53.
2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the
management of arterial hypertension: The Task Force for the Management
of Arterial Hypertension of the European Society of Hypertension (ESH)
and of the European Society of Cardiology (ESC). Eur Heart J
2013;34:2159–2219.
3. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the
management of high blood pressure in adults: Report from the panel mem-
bers appointed to the Eighth Joint National Committee (JNC 8). JAMA
2014;311:507–520.
4. National Institute for Health and Care Excellence. Hypertension: Guidance
and Guidelines. London, UK: National Institute for Health and Care Excel-
lence, 2013.
5. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for
the management of hypertension in the community: A statement by the
American Society of Hypertension and the International Society of Hyper-
tension. J Hypertens 2014;32:3–15.
6. AronowWS, Fleg JL, Pepine CJ et al. ACCF/AHA 2011 expert consensus doc-
ument on hypertension in the elderly. J Am Soc Hypertens 2011;5:259–352.
7. Chobanian AV. SPRINT results in older patients: How low to go? J Am
Geriatr Soc 2016;315:2669–2670.
8. Herrett E, Gallagher AM, Bhaskaran K et al. Data resource profile: Clinical
practice research datalink (CPRD). Int J Epidemiol 2015;44:827–836.
9. HSCIC. QOF Implementation Dataset and Business Rules - Hypertension
(HYP) Indicator Set [Internet], 2013; 1–25. Available from: https://www.
pcc-cic.org.uk/sites/default/files/articles/attachments/hypertension_ruleset_
v25_1.pdf, Last accessed: 08 December 2016.
10. (WHO) WHO. ICD-10 Version:2015 [Internet]. 2015 [cited 2016 Dec 5].
Available from: http://apps.who.int/classifications/icd10/browse/2015/en
Accessed December 08, 2016.
11. NHS. OPCS Classification of Interventions and Procedures [Internet]. NHS
digital. 2016; 1. Available from: http://www.datadictionary.nhs.uk/web_
site_content/supporting_information/clinical_coding/opcs_classification_
of_interventions_and_procedures.asp Accessed December 08, 2016.
12. Khan NF, Perera R, Harper S et al. Adaptation and validation of the Charl-
son Index for Read/OXMIS coded databases. BMC Fam Pract 2010;11:1–7.
13. Schemper M. Cox analysis of survival data with non-proportional hazard
functions. the Statistician 1992;41:455–465.
14. Schisterman EF, Cole SR, Platt R. Overadjustment bias and unnecessary
adjustment in epidemiologic studies. Epidemiology 2009;20:488–495.
15. National Institute for Health and Care Excellence. Osteoporosis: Assessing
the Risk of Fragility Fracture: Guidance and Guidelines. London, UK:
National Institute for Health and Care Excellence, 2012.
16. Jason P, Fine RJG. A proportional hazards model for the subdistribution of
a competing risk. J Am Stat Assoc 1999;94:496–509.
17. Benetos A, Rossignol P, Cherubini A et al. Polypharmacy in the aging
patient. JAMA 2015;314:170.
18. Altman DG, Andersen PK. Calculating the number needed to treat for tri-
als where the outcome is time to an event. BMJ 1999;319:1492–1495.
19. Feldstein C, Weder AB. Orthostatic hypotension : A common, serious and
underrecognized problem in hospitalized patients. J Am Soc Hypertens
2012;6:27–39.
20. Clarke R, Shipley M, Lewington S et al. Underestimation of risk associa-
tions due to regression dilution in long-term follow-up of prospective stud-
ies. Am J Epidemiol 1999;150:341–353.
21. Health and Social Care Information Centre. National Quality and Out-
comes Framework Statistics for England—2004–05 [on-line]. Available at
http://www.hscic.gov.uk/catalogue/PUB0194620 Accessed June 29, 2016.
22. Musini V, Tejani A, Bassett K et al. Pharmacotherapy for hypertension in
the elderly. Cochrane Database Syst Rev 2009;4:CD000028.
23. Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of
twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-
specific associations in 125 million people. Lancet 2014;383:1899–1911.
24. Prospective Studies Collaboration. Age-specific relevance of usual blood
pressure to vascular mortality: A meta-analysis of individual data for one
million adults in 61 prospective studies. Lancet 2002;360:1903–1913.
25. Mancia G, Grassi G. Aggressive blood pressure lowering is dangerous: The
J-curve: Pro side of the argument. Hypertension 2014;63:29–35.
26. Messerli FH. Dogma disputed: Can aggressively lowering blood pressure in
hypertensive patients with coronary artery disease be dangerous? Ann
Intern Med 2006;144:884.
27. Panjrath GS, Chaudhari S, Messerli FH. The J-point phenomenon in
aggressive therapy of hypertension: New insights. Curr Atheroscler Rep
2012;14:124–129.
28. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in
patients 80 years of age or older. N Engl J Med 2008;358:1887–1898.
29. Williamson JD, Supiano MA, Applegate WB et al. Intensive vs standard
blood pressure control and cardiovascular disease outcomes in adults aged
≥ 75 years: A randomized clinical trial. JAMA 2016;315:2673–2682.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
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Figure S2. Risk of all-cause mortality according to sys-
tolic blood pressure stratified according to diastolic blood
pressure (DBP) in individuals aged 80 and older.
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